Company / Return on Assets (ROA)
NEKTAR THERAPEUTICS Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-58.5%
FY2025
5-year range
-131.6% / -46.9%
FY2021-FY2025
Trend
+35.6%
vs FY2024
Sector context
#189 of 213
Health Care
What the data says
NEKTAR THERAPEUTICS's return on assets (roa) of -58.5% is lower than 89% of companies in the Health Care sector (FY2025). Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -131.6% in FY2023 to 44.3% in FY2020.
Based on SEC 10-K filings.
-58.5% in FY2025 with a 5-year CAGR of -102.8%.
Improved from -131.6% to -58.5% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -6.7pp
- 5-Year Change
- -102.8pp
- 10-Year Change
- -
Sector benchmark
-142.1% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 35.6% year-over-year.
- Currently 34.3pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
- Lowest return on assets (roa) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -58.5% | +35.6% |
| FY2024 | -90.8% | +31.0% |
| FY2023 | -131.6% | -154.0% |
| FY2022 | -51.8% | -10.5% |
| FY2021 | -46.9% | -205.9% |
| FY2020 | 44.3% | +1005.5% |
| FY2019 | -4.9% | +31.5% |
| FY2018 | -7.1% | +62.4% |
| FY2017 | -19.0% | -100.4% |
| FY2016 | -9.5% | +41.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026